Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
Denali Therapeutics entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $195 million. The voucher was awarded by the FDA following the March 2026 accelerated approval of AVLAYAH for the treatment of Hunter syndrome.
Key figures
- Deal Value Usd
- 195000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.